Preprint Fibromyalgia, [CFS], and Multiple Sclerosis are associated with lower translocator protein binding affinity genotypes, 2026, Jones, Younger et al

forestglip

Administrator
Staff member
Fibromyalgia, Chronic Fatigue Syndrome, and Multiple Sclerosis are associated with lower translocator protein binding affinity genotypes

Jones, Chloe; Younger, Jarred

Introduction
Neuroinflammation is a known pathophysiologic mechanism in multiple sclerosis and a proposed mechanism in fibromyalgia and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

Positron Emission Tomography (PET) imaging of the translocator protein (TSPO) has been widely used to measure neuroinflammation, though second-generation ligands are highly sensitive to a single nucleotide polymorphism, rs6971, resulting in high, mixed, and low affinity binders. It is unknown whether this polymorphism is associated with neuroinflammatory disorders.

Materials and Methods
Eighty-six total participant genotypes for TSPO binding affinity were identified through Sanger sequencing (30 fibromyalgia, 21 ME/CFS, 11 multiple sclerosis, and 24 healthy controls). Associations between patient group and genotype were assessed with Fisher’s Exact test. Associations between genotype and symptom severity from self-report questionnaires were assessed with Kruskal-Wallis tests.

Results
In the present study individuals with fibromyalgia, (ME/CFS), or multiple sclerosis were more likely to have a mixed- or low-affinity genotypes compared to healthy controls. Presence of the low or mixed genotypes were also associated with greater self-reported fatigue severity and depressive symptoms.

Discussion
These findings should be confirmed in larger samples but suggest functional consequences of rs6971 polymorphism that may be related to the pathophysiology of pain and fatigue illnesses.

Web | DOI | PDF | medRxiv | Preprint
 
The rs6971 SNP has been primary investigated in psychiatric illness due to its potential influence on HPA axis regulation. The SNP has been associated with higher rates of bipolar disorder [33], variance in diurnal cortisol rhythms in bipolar disorder [34], and higher cholesterol, low density lipoprotein (LDL), triglycerides, and withdrawal symptoms in alcohol use disorder [35]. Presence of the polymorphism has also been associated with separation anxiety [36], and panic disorder [37]. In addition to psychiatric illness, the SNP has been associated with poorer prognosis in male glioblastoma patients [38] and is possibly related to Parkison’s disease progression [39].
 
They note that prevalence of this variant varies by ancestry, and that the study sample was diverse with regard to ancestry, but they don't seem to actually report the ancestries of the four groups separately. That seems like a very important thing to include, as the findings could be related to different ancestries in the groups.
The sample was 71.43% Caucasian/White (n = 60), 23.81% African-American/Black (n = 20), and 4.76% Asian (n = 4). Two participants did not report their race/ethnicity.
The TSPO SNP is also known to vary by ancestry; East-Asian populations show the lowest rates of the alternate allele polymorphism (96.9% high affinity binders), followed by African populations (67.4% high affinity binders), American populations (69.2% high affinity binders) and the greatest rates of the polymorphism is found in European populations (45.7% high affinity binders) [44].
Although the present study compared genotypes across racial/ethnic groups, future studies should include more diverse and balanced samples, and collect more detail on ethnic background. Ethnicity was also self-reported by participants who may not know or fully disclose their ethnic makeup.
 
Last edited:
This have something to do with Michelle James’s research, don't it?
....
I came across this study on Klein-Levine syndrome wich use the same ligand and group patients by affinity. It helped rule out the neuroinflammation hypothesis. They also point out that the ligand measures microglial density over all.
Pet study of microglial activation in Klein-Levin Syndrome

But shortly afterwards, I realise that this study on KLS – given the rarity of patients – isn’t all that easy to carry out, but it should already have been done and redone for us.
Suddenly, I can’t understand why it’s such a free-for-all when it comes to us. Reading studies and findings on other conditions, it seems to me that things can be done properly and without beating about the bush.
 
Back
Top Bottom